Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Opioids: US Senate Committee Chairman's Discussion Drafts Broadly Reflect FDA Priorities

Executive Summary

Agency would be allowed to require blister packaging for approved opioids, and would have to do more to coordinate with US Customs and Border Protection to detect illicit drugs at the border, under legislative proposals unveiled by Senate HELP Committee Chairman Lamar Alexander.

Advertisement

Related Content

Senate Draft Bill On Opioids Tasks US FDA With Clarifying Its Regulation Of New Treatments
Gottlieb Showing Capitol Hill Skills With Funding Success
Bipartisan Consensus Emerges To Let FDA Destroy Unlabeled Illicit Opioids
New US FDA Powers On Rx Abuse Could Be 'Tailored' By Congress, Gottlieb Suggests
Proposed Legislation Would Help FDA Stop Illicit Opioids At Border -- And More
Charleston's Anti-Emetic/Opioid Combo Flops At US FDA Panel Over Postmarketing, Dosage Concerns
US FDA Proactively Exploring Hydexor Abuse Potential Ahead Of Ad Comm For Anti-Emetic/Opioid Combo
Opioid Packaging Standards Could Emerge From Dosage Guidelines in Labeling
FDA Expanding Opioid REMS To Immediate Release Formulations

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS122785

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel